Technical Analysis for AMGN - Amgen Inc.

Grade Last Price % Change Price Change
F 240.20 -1.56% -3.80
AMGN closed down 1.56 percent on Wednesday, February 8, 2023, on approximately normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction -1.56%
Earnings Movers Other -1.56%
Calm After Storm Range Contraction -1.50%
Earnings Movers Other -1.50%
Inside Day Range Contraction -1.50%
Slingshot Bearish Bearish Swing Setup -2.03%
Gapped Up Strength -2.03%
Oversold Stochastic Weakness -2.03%
New Downtrend Bearish -2.57%
Hammer Candlestick Bullish -2.57%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
Down 1% about 9 hours ago
2x Volume Pace about 11 hours ago
1.5x Volume Pace about 11 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Amgen Inc. Description

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biotechnology Nasdaq 100 Drugs Pharmaceutical Products Clinic Bone Inflammation Monoclonal Antibody Neuroscience Healthcare Providers Prostate Cancer Dow Jones Component Inflammatory Diseases Therapeutic Products Hematology Wholesale Distributor Dialysis Epidermal Growth Factor Receptor Takeda Pharmaceutical Company Red Blood Cell Blood Cells Nephrology Cancer Care Platelet Resistant Prostate Cancer Metastases Bone Disease Mimics Recombinant Proteins Tumor Necrosis Factor Necrosis Tumor Necrosis Castration Resistant Prostate Cancer Growth Factors Human Therapeutic Products

Is AMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 296.63
52 Week Low 214.3915
Average Volume 2,526,617
200-Day Moving Average 252.88
50-Day Moving Average 266.27
20-Day Moving Average 256.53
10-Day Moving Average 247.87
Average True Range 5.24
RSI 20.63
ADX 31.41
+DI 11.04
-DI 33.38
Chandelier Exit (Long, 3 ATRs) 261.11
Chandelier Exit (Short, 3 ATRs) 252.10
Upper Bollinger Bands 276.56
Lower Bollinger Band 236.49
Percent B (%b) 0.09
BandWidth 15.62
MACD Line -6.89
MACD Signal Line -5.51
MACD Histogram -1.3804
Fundamentals Value
Market Cap 139.84 Billion
Num Shares 582 Million
EPS 12.40
Price-to-Earnings (P/E) Ratio 19.37
Price-to-Sales 5.34
Price-to-Book 11.94
PEG Ratio 1.48
Dividend 6.40
Dividend Yield 2.66%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 246.14
Resistance 3 (R3) 246.60 245.08 245.15
Resistance 2 (R2) 245.08 243.57 244.85 244.82
Resistance 1 (R1) 242.64 242.63 241.88 242.18 244.49
Pivot Point 241.12 241.12 240.74 240.89 241.12
Support 1 (S1) 238.68 239.61 237.92 238.22 235.91
Support 2 (S2) 237.16 238.67 236.93 235.58
Support 3 (S3) 234.72 237.16 235.25
Support 4 (S4) 234.26